• CytomX Therapeutics targets a registrational study of Varseta-M in relapsed or refractory metastatic colorectal cancer in the first half of 2027.
• Confirmed objective response rates reached 20% at 8.6 mg/kg and 32% at 10 mg/kg in late-line colorectal cancer.
• Preliminary progression-free survival was 6.8 months at 8.6 mg/kg and 7.1 months at 10 mg/kg.
• A Phase 1/2 trial combining Varseta-M with bevacizumab and chemotherapy is planned to begin by year-end 2026.
• Cash totaled $348 million as of the third quarter of 2026, providing runway into the second half of 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.